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Background: Tuberculosis caused by Mycobacterium tuberculosis (M. 
tuberculosis), remains as one of the leading causes of deaths worldwide, with 
nearly two million death cases annually. BCG (Bacille Calmette-Guerin) 
continues to be the most widely used vaccine in the world, but the protective 
immunity differs in different parts of the world. Accordingly, new strategies 
including DNA vaccines are essentially needed. This study was aimed to design 
and construct a cloning vector containing mpt64 gene of M. tuberculosis. 
Materials and Methods: M. tuberculosis H37Rv was cultured on Lowenstein 
Jensen medium, and genomic DNA was extracted. The mpt64 gene was 
amplified by PCR using designed specific primers. After the digestion of mpt64 
and pcDNA3.1 (+) by BamHI and EcoRI restriction enzymes, the mpt64 fragment 
was ligated into the digested vector using T4 DNA ligase enzyme. Then, the 
recombinant vector was transformed into competent Escherichia coli (E. coli) 
TOP10 strain. To confirm the colonies of transformed bacteria, antibiotic 
resistance, colony-PCR, restriction enzyme digestion and DNA sequencing 
were used. 
Results: To confirm the clones, colony-PCR using mpt64 specific primers was 
performed and the fragment of 718 bp was observed by gel electrophoresis. 
Clones were also verified by restriction enzyme digestion using BamHI and 
EcoRI restriction enzymes and the 718 bp fragment was observed. Furthermore, 
results of DNA sequencing showed 100% homology with the mpt64 fragment of 
H37Rv in GenBank. 
Conclusion: In this study, the mpt64 fragment was successfully cloned in 
pcDNA3.1 (+) vector. This construct can be used in future studies as a DNA 
vaccine in animal models to induce immune system responses. 
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INTRODUCTION 
Tuberculosis (TB) is a major global health problem 
caused by Mycobacterium tuberculosis (M. tuberculosis) 
(MTB). According to latest report of World Health 
Organization (WHO), 6.3 million new cases of TB and 1.7 
million deaths were reported in 2016 (1,2). The 
Mycobacterium bovis (M. bovis) Bacillus Calmette–Guerin 
(BCG) is the current vaccine of TB which has been included 
in Immunization Programs since 1974 (3). BCG provides 
variable protective efficacies ranging from 0 to 80% in 
different parts of the world and it has a low level of 
protection against pulmonary TB (4). The variability in 
BCG’s protective efficacy may be resulted from strain 
variations in BCG preparations and environmental 
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mycobacteria (5). For these reasons, new TB vaccines must 
be studied. Currently, new vaccines for TB are being 
developed such as recombinant BCG, subunit, and DNA 
vaccines (6,7). 
Cell wall and secreted proteins of M. tuberculosis, the 
main antigens which are recognized by host immune 
system, are the candidates for developing DNA vaccines 
and this type of vaccines have been used to induce 
immune responses or as boosters after BCG vaccination 
(8,9). DNA vaccines encoded epitopes are expressed 
through major histocompatibility complex (MHC) mol-
ecules. Next, helper and cytotoxic T cells recognize the 
MHCI-antigen complex and strong responses of CD4+ 
(Th1) and CD8+ (CTL) can be induced by DNA vaccines 
against M. tuberculosis (10). Use of these antigens for the 
diagnosis of both active and latent TB is suggested in 
recent studies. The Regions of Differences (RD) encoded 
proteins are among such antigens. Some of these regions of 
differences which encode antigens are present in the 
genome of M. tuberculosis, M. bovis, and Mycobacterium 
africanum (M. africanum), but absent in all BCG substrains 
genome (11).  
ESAT-6 (Rv3875), CFP10 (Rv3874), MPT64 (Rv1980c), 
and CFP21 (Rv1984c) have been considered as the main 
immunodominant antigens which are encoded by RD1 and 
RD2 of M. tuberculosis, respectively (12). MPT64 is one of 
the best-characterized antigens in RD2 (the second absent 
region from the original BCG strains) and a major secreted 
protein in the early culture filtrate of M. tuberculosis that 
accounts for about 8% of the total culture filtrate protein. 
This protein consists of 228 amino acids with molecular 
weight of 24.8 kDa that has superoxide dismutase and 
strong cellular immune activity (13,14). This study was 
aimed to design and construct a cloning vector containing 
mpt64 gene of M. tuberculosis strain H37Rv. 
 
MATERIALS AND METHODS 
DNA Extraction and Polymerase Chain Reaction 
M. tuberculosis strain H37Rv was cultured on 
Lowenstein Jensen (LJ) medium and was incubated for six 
weeks at 37˚C. DNA extraction was performed using 
boiling method (15).  
The mpt64 primers were designed by Gene Runner 
software and were synthesized by CinnaGen Company of 
Iran. The mpt64 gene amplification was performed using 
the following primers, forward: 
5′TATTTCGGATCCACCATGGGACGCATCAAGATCTTCAT-3′  
and reverse: 
5′-CATATATGAATTCCTAGGCCAGCATCGAGTCGATCGCGGAAC-3′ 
(BamHI and EcoRI restriction sites are underlined). The 25 
μl PCR reaction mixture contained 1 μl of 100 ng/μl 
genomic extracted DNA, 0.5 μl of 10mM dNTPs 
(CinnaGen, Iran), 2.5 μl of 10x PCR buffer (ParsTous, Iran), 
1.5 μl of 25mM MgCl2 (ParsTous, Iran), 0.2 μl of 5U/μl Taq 
DNA polymerase (CinnaGen, Iran), and 1.0 μl of each 10 μM 
primer (CinnaGen, Iran).  
The DNA amplification involved initial denaturation at 
95°C for 4 min, proceeded by 35 cycles of denaturation at 
94°C for 30 sec, annealing at 60°C for 30 sec, extension at 
72°C for 45 sec, followed by final extension at 72°C for 
seven minutes. Then, 100 μL of the PCR product was 
electrophoresed on 1% agarose gel and the mpt64 fragment 
purification was performed using AccuPrep® Gel 
Purification Kit (Bioneer, Korea). 
Cloning of mpt64 fragment into pcDNA3.1 (+) vector 
Both pcDNA3.1 (+) plasmid and PCR product were 
digested by BamHI and EcoRI restriction enzymes (Thermo 
Scientific, Germany) by the reaction of 20 μL purified PCR 
product, 10 μL of 10x Tango Buffer, 2 μL BamHI (5 U/μL), 
2 μL EcoRI (5 U/μL), and deuterium-depleted water 
(DDW) up to final volume of 50 μL for PCR product 
enzymatic digestion. Also, the reaction of 5 μL pcDNA3.1 
(+), 4 μL 10x Tango Buffer, 1 μL BamHI (5 U/μL), 1 μL 
EcoRI (5 U/μL), and DDW up to final volume of 20 μL was 
prepared for plasmid enzymatic digestion. The digested 
products were electrophoresed and purified by AccuPrep® 
Gel Purification Kit (Bioneer, Korea). 
The digested mpt64 PCR product was ligated into the 
digested vector using T4 DNA ligase enzyme in a reaction 
of 8 μL digested mpt64 fragment, 14.5 μL digested 
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pcDNA3.1 (+) vector, 2.5 μL T4 DNA ligase buffer, 0.2 μL 
T4 DNA ligase (150 U/μL) (Metabion, Germany) and 2 μL 
of the polyethylene glycol (PEG) 4000 (Thermo Scientific, 
Germany). After ligation, the competent cells of Escherichia 
coli (E. coli) strain TOP10 was prepared by cold treatment 
of 0.1 M CaCl2/MgCl2 solution, and the competency made 
for acquiring DNA. The prepared E. coli competent cells 
were transformed by recombinant vector using the heat 
shock method (16). This step also included positive and 
negative controls for validating the process of competent 
cell preparation. The transformed bacteria were cultured 
on LB agar medium containing ampicillin by concentration 
of 100 μg/mL and were incubated at 37°C overnight. 
Colonies acquiring the recombinant vector were confirmed 
using Colony-PCR. The recombinant plasmid was 
extracted from positive clones using GeneJET Plasmid 
Miniprep Kit (Thermo Scientific, Germany). The clones 
were also confirmed using enzymatic digestion by BamHI 
and EcoRI restriction enzymes. For final confirmation, 
DNA sequencing was carried out by SeqLab co. (Germany) 
and the results were analyzed by BioEdit software. 
 
RESULTS 
In this study, we amplified M. tuberculosis strain H37Rv 
mpt64 gene by PCR method and fragment of 718 bp was 
observed by gel electrophoresis (Figure 1). After gel 
purification of PCR product, single and double digestions 
were performed on the product. 
After digestion of PCR product by BamHI and EcoRI, 
the desired fragment was observed by gel electrophoresis. 
The pcDNA3.1 (+) vector was also digested with both 
BamHI and EcoRI and a band relating to 5428 bp was 
observed. Then, mpt64 fragment was ligated into the 
pcDNA3.1 (+) vector by T4 DNA ligase enzyme. The 
ligation product was used to transform E. coli TOP10 strain 
using cold 0.1 M CaCl2/ MgCl2 solution and transformed 
bacteria were cultured on ampicillin included LB agar. 
Colony-PCR was performed using mpt64 specific primers 
to confirm insertion of our fragment into the vector and the 
718 bp fragment was observed by gel electrophoresis. 
Purification of recombinant vector was performed by 
GeneJET Plasmid Miniprep Kit (Thermo Scientific, 
Germany) and the same fragment was observed in gel 
electrophoresis for the extracted plasmid PCR by mpt64 
specific primers. Then the recombinant vector was 
subjected to double digestion with BamHI and EcoRI, so the 
insert cut out and was observed by gel electrophoresis. 
Final confirmation was based on DNA sequencing of 
recombinant vector. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. PCR product agarose gel electrophoresis (1% w/v). Lane M: 1 kb DNA 
Ladder (Thermo Scientific, Germany); Lane 1: positive control of PCR; Lane 2: 
negative control of PCR; Lane 3: 718 bp PCR product of mpt64 fragment 
 
DISCUSSION  
The long duration of conventional chemotherapy of TB, 
together with the increasing incidence of drug-resistant 
strains and co-infection with HIV, points to an urgent need 
for new strategies against TB (17). BCG is the only 
available vaccine and a live attenuated one which has been 
used since 1921 (18). Despite the worldwide use, it has 
some limitations such as low level of protection in 
pulmonary TB. So, TB remains as the major public health 
problem (18,19). Thus, new effective and reliable vaccines 
are needed. In this regard, several strategies including 
DNA vaccines, recombinant BCG vaccines, and subunit 
vaccines are being developed. They are intended to replace 
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the BCG vaccine or as the boosters after BCG vaccination 
(20).  
The secreted and cell wall proteins of M. tuberculosis 
including MPT64, HSP, Esat-6, Ag85, PstS-3 which 
recognized by immune system of host, could be the 
candidates for developing DNA vaccines (13,21).  
Mahairas and colleagues demonstrated the M. 
tuberculosis specific genomic regions for the first time in 
1996. Their studies showed that three specific regions in 
the genome of M. tuberculosis and M. bovis, were absent 
from BCG genome and were called regions of difference 
(RD1, RD2, and RD3) (22). 
MPT64 (Rv1980c), an important immunodominant 
antigen with superoxide dismutase activity and a strong 
cellular immune activity, is encoded by RD2 of M. 
tuberculosis and included in recent vaccine-related studies. 
This protein has 228 amino acids with the molecular 
weight of 24.8 kDa (14). 
Yu et al, in a study on the Ag85B/MPT64/MPT83 DNA 
vaccine, showed that the vaccine provides good protection 
in mice following the exposure to H37Rv antigens. 
According to their research, the use of DNA vaccine is 
valuable to reduce the course of treatment (23). 
Bai and colleagues expressed the fusion genes of esat-6 
and mpt64 in E. coli. It was observed that the fusion protein 
of ESAT-6/MPT64 increases Th1 response more than 
MPT64. It was resulted that the more epitopes detected, the 
stronger immune responses would occur (24).  
Bao et al. has successfully constructed the 
Ag85A/MPT64 DNA vaccine. Their results showed that 
animal challenge would produce specific antibodies (13). 
Tian et al showed that the DNA vaccine encoding 
Ag85B and MPT64 increased the IgG titers in immunized 
C57BL/6 mice to very high level only after the second 
injection (25). 
Fan and colleagues showed that MPT64 could activate 
RAW264.7 macrophage to induce cytokines significantly 
(7).  
In this study, we cloned mpt64 fragment into the 
eukaryotic pcDNA3.1 (+) vector to be used as a DNA 
vaccine. In further studies, immunization can be 
considered as a DNA vaccine in laboratory animal models.  
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